secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093920
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus reports Q2 net loss $17.6M; cash $360.7M funds pipeline into 2H'27
---------------------------------------------------------------------------

- Net loss $17.6M ($0.51/share) vs $11.1M ($12.73/share) in Q2 2023.
- Cash, equivalents & short-term investments $360.7M as of June 30, 2024, projected runway into 2H'27.
- Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H'25.
- IND cleared for Phase 2 MoMeNtum trial in MMN; top-line results anticipated 2H'26.
- Alison Lawton appointed Chair of Board, effective July 1, 2024, succeeding Lonnie Moulder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024093920/0000950170-24-093920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024093920/dnth-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer